| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marzieh Salehi, Amalia Gastaldelli, David A D'Alessi. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology. vol 146. issue 3. 2014-05-27. PMID:24315990. |
these patients also have increased postprandial levels of insulin and glucagon-like peptide 1 (glp-1). |
2014-05-27 |
2023-08-12 |
Not clear |
| Michela Riz, Morten Gram Pedersen, Gianna Maria Toffolo, Guido Haschke, Hans-Christoph Schneider, Thomas Klabunde, Daniel Margerie, Claudio Cobell. Minimal modeling of insulin secretion in the perfused rat pancreas: a drug effect case study. American journal of physiology. Endocrinology and metabolism. vol 306. issue 6. 2014-05-27. PMID:24425760. |
the model was initially applied to untreated pancreata and afterward used for the assessment of pharmacologically relevant agents (the gut hormone glp-1, the potent glp-1 receptor agonist lixisenatide, and a gpr40/ffar1 agonist, sar1) to quantify and differentiate their effect on insulin secretion. |
2014-05-27 |
2023-08-12 |
rat |
| Toshiyasu Sasaoka, Tsutomu Wada, Hiroshi Tsunek. [Insulin resistance and cognitive function]. Nihon rinsho. Japanese journal of clinical medicine. vol 72. issue 4. 2014-05-27. PMID:24796090. |
nasal insulin administration, thiazolidinedione, and glp-1 receptor agonist possess neuronal protective effects in the treatment of mild cognitive dysfunction. |
2014-05-27 |
2023-08-13 |
Not clear |
| Richard D Mattes, Robert V Considin. Oral processing effort, appetite and acute energy intake in lean and obese adults. Physiology & behavior. vol 120. 2014-05-26. PMID:23954409. |
the present trial manipulated oral processing effort though required chewing of gums of different hardness and measured appetitive sensations, energy intake, gastric emptying, gi transit time, and concentrations of glucose, insulin, glp-1, ghrelin and pancreatic polypeptide. |
2014-05-26 |
2023-08-12 |
human |
| Timothy D Heden, Ying Liu, Monica L Kearney, Youngmin Park, Kevin C Dellsperger, Tom R Thomas, Jill A Kanale. Prior exercise and postprandial incretin responses in lean and obese individuals. Medicine and science in sports and exercise. vol 45. issue 10. 2014-05-21. PMID:23559122. |
the incretin hormones glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) help regulate postprandial triacylglycerol (tag) and insulin concentrations, but the effects of acute aerobic exercise on glp-1 or gip responses are unclear. |
2014-05-21 |
2023-08-12 |
Not clear |
| Timothy D Heden, Ying Liu, Monica L Kearney, Youngmin Park, Kevin C Dellsperger, Tom R Thomas, Jill A Kanale. Prior exercise and postprandial incretin responses in lean and obese individuals. Medicine and science in sports and exercise. vol 45. issue 10. 2014-05-21. PMID:23559122. |
the purpose of this study was to determine whether reductions in postprandial tag and insulin with exercise are associated with glp-1 and gip responses. |
2014-05-21 |
2023-08-12 |
Not clear |
| Masahiro Iwasaki, Kohtaro Minami, Tadao Shibasaki, Takashi Miki, Jun-Ichi Miyazaki, Susumu Sein. Establishment of new clonal pancreatic β-cell lines (MIN6-K) useful for study of incretin/cyclic adenosine monophosphate signaling. Journal of diabetes investigation. vol 1. issue 4. 2014-05-20. PMID:24843422. |
despite the difference in incretin-potentiated insulin secretion between these two cell lines, the accumulation of camp after stimulation of glp-1 is comparable in these cells. |
2014-05-20 |
2023-08-13 |
mouse |
| Norio Harada, Akihiro Hamasaki, Shunsuke Yamane, Atsushi Muraoka, Erina Joo, Kazuyo Fujita, Nobuya Inagak. Plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels after glucose loading are associated with different factors in Japanese subjects. Journal of diabetes investigation. vol 2. issue 3. 2014-05-20. PMID:24843483. |
aims/introduction: gastric inhibitory polypeptide (gip) and glucagon-like peptide-1 (glp-1) are major incretins that potentiate insulin secretion from pancreatic β-cells. |
2014-05-20 |
2023-08-13 |
human |
| Yukio Horikawa, Mayumi Enya, Katsumi Iizuka, Gui Ying Chen, Shin-Ichi Kawachi, Tetsuya Suwa, Jun Taked. Synergistic effect of α-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment. Journal of diabetes investigation. vol 2. issue 3. 2014-05-20. PMID:24843484. |
in the present study, we evaluated the combined effects of various of α-gi inhibitors (acarbose, voglibose or miglitol) and sitagliptin, a dpp4 inhibitor, on blood glucose fluctuation, insulin and active glucagon-like peptide-1 (glp-1) levels after nutriment loading in mice. |
2014-05-20 |
2023-08-13 |
mouse |
| Lindsay B Harrison, Pablo F Mora, Gregory O Clark, Ildiko Lingva. Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. vol 61. issue 1. 2014-05-19. PMID:23222002. |
type 1 diabetes treatment beyond insulin: role of glp-1 analogs. |
2014-05-19 |
2023-08-12 |
Not clear |
| A Samat, S K Malin, H Huang, P R Schauer, J P Kirwan, S R Kashya. Ghrelin suppression is associated with weight loss and insulin action following gastric bypass surgery at 12 months in obese adults with type 2 diabetes. Diabetes, obesity & metabolism. vol 15. issue 10. 2014-05-19. PMID:23679188. |
changes in ghrelin, body weight, glucagon-like polypeptide-1 (glp-1, glucose tolerance and insulin sensitivity (is) were measured. |
2014-05-19 |
2023-08-12 |
human |
| Elisabetta Bianchi, Paul E Carrington, Paolo Ingallinella, Marco Finotto, Alessia Santoprete, Aleksandr Petrov, George Eiermann, Jennifer Kosinski, Donald J Marsh, Alessandro Pocai, Ranabir SinhaRoy, Antonello Pess. A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity. Bioorganic & medicinal chemistry. vol 21. issue 22. 2014-05-14. PMID:24094437. |
peptide agonists of the glucagon-like peptide 1 (glp-1) receptor (glp1r) are rapidly gaining favor as antidiabetic agents, since in addition to increasing glucose-dependent insulin secretion, they also cause weight loss. |
2014-05-14 |
2023-08-12 |
mouse |
| Franca S Angeli, Richard P Shanno. Incretin-based therapies: can we achieve glycemic control and cardioprotection? The Journal of endocrinology. vol 221. issue 1. 2014-05-12. PMID:23926280. |
glp-1 stimulates insulin secretion in a glucose-dependent manner, inhibits glucagon secretion and gastric emptying, and reduces appetite. |
2014-05-12 |
2023-08-12 |
Not clear |
| Christian Hölsche. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. The Journal of endocrinology. vol 221. issue 1. 2014-05-12. PMID:23999914. |
glp-1 also has very similar growth-factor-like properties to insulin, which is presumably the underlying basis of the neuroprotective effects. |
2014-05-12 |
2023-08-12 |
Not clear |
| Katja Piotrowski, Melanie Becker, Julia Zugwurst, Ingeborg Biller-Friedmann, Gerald Spoettl, Martin Greif, Alexander W Leber, Alexander Becker, Rüdiger P Laubender, Corinna Lebherz, Burkhard Goeke, Nikolaus Marx, Klaus G Parhofer, Michael Lehrk. Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans. Cardiovascular diabetology. vol 12. 2014-05-07. PMID:23953602. |
glp-1 is an incretine hormone which gets secreted from intestinal l-cells in response to nutritional stimuli leading to pancreatic insulin secretion and suppression of glucagon release. |
2014-05-07 |
2023-08-12 |
Not clear |
| Aljoša Bave. (Poly)peptide-based therapy for diabetes mellitus: insulins versus incretins. Life sciences. vol 99. issue 1-2. 2014-05-05. PMID:24412390. |
contrary, glp-1 mimetic therapy improves postprandial glycaemia without the hypoglycaemia and weight gain associated with aggressive insulin therapy. |
2014-05-05 |
2023-08-12 |
Not clear |
| Aljoša Bave. (Poly)peptide-based therapy for diabetes mellitus: insulins versus incretins. Life sciences. vol 99. issue 1-2. 2014-05-05. PMID:24412390. |
thus, a right combination of basal insulin which has lowering effect on fasting plasma glucose and glp-1 mimetic with its lowering effect on postprandial plasma glucose with minimal gastrointestinal adverse effects, seems the right therapy choice from a clinical point of view for some diabetic patients. |
2014-05-05 |
2023-08-12 |
Not clear |
| Aljoša Bave. (Poly)peptide-based therapy for diabetes mellitus: insulins versus incretins. Life sciences. vol 99. issue 1-2. 2014-05-05. PMID:24412390. |
in this article, we discuss the pros and cons of the use of insulin analogues and glp-1 mimetics that are associated with the treatment of type 2 diabetes. |
2014-05-05 |
2023-08-12 |
Not clear |
| Naim Shehadeh, Eena Daich, Nehama Zuckerman-Levi. Can GLP-1 preparations be used in children and adolescents with diabetes mellitus? Pediatric endocrinology reviews : PER. vol 11. issue 3. 2014-05-01. PMID:24716398. |
glucagon-like peptide-1 (glp-1) is secreted from the gut after meals and enhances glucose-induced insulin secretion, inhibits glucagon secretion, suppresses appetite, and delays the gastric-emptying rate. |
2014-05-01 |
2023-08-13 |
human |
| Yao Dai, Jawahar L Mehta, Mingwei Che. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovascular drugs and therapy. vol 27. issue 5. 2014-04-28. PMID:23657563. |
glucagon-like peptide-1 (glp-1) activation stimulates insulin secretion and may prevent atherosclerosis by increasing enos synthesis. |
2014-04-28 |
2023-08-12 |
Not clear |